Latest Insider Transactions at Checkmate Pharmaceuticals, Inc. (CMPI)
This section provides a real-time view of insider transactions for Checkmate Pharmaceuticals, Inc. (CMPI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Checkmate Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Checkmate Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
95,800
-4.25%
|
$958,000
$10.45 P/Share
|
|
May 13
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,850
-1.57%
|
$358,500
$10.45 P/Share
|
|
May 12
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
124,525
-5.16%
|
$1,245,250
$10.39 P/Share
|
|
May 11
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
17,700
-0.73%
|
$177,000
$10.38 P/Share
|
|
May 10
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
18,676
-0.76%
|
$186,760
$10.38 P/Share
|
|
May 09
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
17,600
-0.71%
|
$176,000
$10.37 P/Share
|
|
May 06
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
48,334
-1.92%
|
$483,340
$10.37 P/Share
|
|
May 05
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,743
-0.82%
|
$207,430
$10.37 P/Share
|
|
May 04
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
37,500
-1.46%
|
$375,000
$10.37 P/Share
|
|
May 03
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
79,475
-3.0%
|
$794,750
$10.37 P/Share
|
|
May 02
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
153,700
-5.48%
|
$1,537,000
$10.38 P/Share
|
|
Apr 29
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
69,230
-2.41%
|
$692,300
$10.38 P/Share
|
|
Apr 28
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
73,400
-2.49%
|
$734,000
$10.38 P/Share
|
|
Apr 27
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
47,396
-1.58%
|
$473,960
$10.38 P/Share
|
|
Apr 26
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
64,683
-2.11%
|
$646,830
$10.38 P/Share
|
|
Apr 25
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
27,668
-0.9%
|
$276,680
$10.39 P/Share
|
|
Apr 22
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
37,430
-1.2%
|
$374,300
$10.39 P/Share
|
|
Apr 21
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
62,200
-1.95%
|
$622,000
$10.38 P/Share
|
|
Apr 20
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
85,611
-2.62%
|
$856,110
$10.39 P/Share
|
|
Apr 19
2022
|
Ven Bio Global Strategic Fund Ii L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
399,923
-10.89%
|
$3,999,230
$10.42 P/Share
|
|
Feb 25
2022
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
300
-0.01%
|
$600
$2.7 P/Share
|
|
Feb 24
2022
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,990
-0.28%
|
$11,980
$2.83 P/Share
|
|
Feb 23
2022
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,820
-0.08%
|
$3,640
$2.9 P/Share
|
|
Jun 18
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
7,224
+0.88%
|
$43,344
$6.04 P/Share
|
|
Jun 16
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
3,578
+0.44%
|
$21,468
$6.18 P/Share
|
|
May 28
2021
|
Arthur M Krieg Chief Scientific Officer |
SELL
Other acquisition or disposition
|
Indirect |
205,371
-100.0%
|
-
|
|
May 18
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
25,001
+3.01%
|
$150,006
$6.97 P/Share
|
|
Mar 29
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
33,220
+2.11%
|
$365,420
$11.17 P/Share
|
|
Mar 26
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
3,484
+0.46%
|
$41,808
$12.15 P/Share
|
|
Mar 25
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
10,036
+1.33%
|
$120,432
$12.35 P/Share
|
|
Feb 26
2021
|
Kleem Chaudhary Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+20.0%
|
$4,000
$2.62 P/Share
|
|
Jan 27
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,701
+0.23%
|
$22,113
$13.05 P/Share
|
|
Jan 19
2021
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
500
+0.07%
|
$6,500
$13.09 P/Share
|
|
Jan 14
2021
|
Kleem Chaudhary Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+25.0%
|
$4,000
$2.62 P/Share
|
|
Dec 29
2020
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
443
+0.06%
|
$6,202
$14.16 P/Share
|
|
Dec 22
2020
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,103
+0.69%
|
$71,442
$14.64 P/Share
|
|
Dec 22
2020
|
Kleem Chaudhary Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+50.0%
|
$8,000
$2.62 P/Share
|
|
Dec 16
2020
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
4,805
+0.66%
|
$67,270
$14.62 P/Share
|
|
Dec 15
2020
|
Arthur M Krieg Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
42
+0.01%
|
$588
$14.49 P/Share
|
|
Aug 11
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500,000
+18.73%
|
$7,500,000
$15.0 P/Share
|
|
Aug 11
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,670,100
+50.0%
|
-
|